Skip to main content
Retour
ALKS logo

Alkermes plc

Qualité des données : 100%
ALKS
NASDAQ Healthcare Biotechnology
28,40 €
▲ 0,69 € (2,49%)
Cap. Boursière : 4,73B
Fourchette du Jour
27,31 € 28,52 €
Fourchette 52 Semaines
25,17 € 36,32 €
Volume
2 999 226
Moyenne 50J / 200J
31,35 € / 29,72 €
Clôture Précédente
27,71 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E 19,6 0,3
P/B 2,6 2,9
ROE % 14,7 3,7
Net Margin % 16,4 3,8
Rev Growth 5Y % 5,9 10,0
D/E 0,0 0,2

Objectif de Cours des Analystes

Hold
46,83 € +64.9%
Low: 43,00 € High: 56,00 €
BPA Prévisionnel
-0,31 €
CA Est.
1,8 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 3,17 €
3,06 € – 3,39 €
2,5 B 4
FY2029 2,18 €
2,10 € – 2,33 €
2,3 B 4
FY2028 1,45 €
-0,26 € – 3,89 €
2 B 10

Points Clés

Revenue grew 5,89% annually over 5 years — modest growth
Earnings declined -34,16% over the past year
ROE of 14,72% — decent returns on equity
Net margin of 16,37% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 480,33M in free cash flow

Croissance

Revenue Growth (5Y)
5,89%
Revenue (1Y)-5,25%
Earnings (1Y)-34,16%
FCF Growth (3Y)16,60%

Qualité

Return on Equity
14,72%
ROIC10,08%
Net Margin16,37%
Op. Margin17,21%

Sécurité

Debt / Equity
0,04
Current Ratio3,55
Interest Coverage20,69

Valorisation

P/E Ratio
19,58
P/B Ratio2,60
EV/EBITDA14,50
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -5,25% Revenue Growth (3Y) -5,80%
Earnings Growth (1Y) -34,16% Earnings Growth (3Y) -17,58%
Revenue Growth (5Y) 5,89% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,48B Net Income (TTM) 241,66M
ROE 14,72% ROA 9,55%
Gross Margin 86,31% Operating Margin 17,21%
Net Margin 16,37% Free Cash Flow (TTM) 480,33M
ROIC 10,08% FCF Growth (3Y) 16,60%
Safety
Debt / Equity 0,04 Current Ratio 3,55
Interest Coverage 20,69 Dividend Yield 0,00%
Valuation
P/E Ratio 19,58 P/B Ratio 2,60
P/S Ratio 3,21 PEG Ratio -0,56
EV/EBITDA 14,50 Dividend Yield 0,00%
Market Cap 4,73B Enterprise Value 3,68B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,48B 1,56B 1,66B 1,11B 1,17B
Net Income 241,66M 367,07M 355,76M -158,27M -48,17M
EPS (Diluted) 1,43 2,17 2,10 -0,97 -0,30
Gross Profit 1,27B 1,31B 1,41B 893,73M 976,43M
Operating Income 253,96M 420,64M 414,12M -6,09M 97,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,53B 2,06B 2,14B 1,96B 2,02B
Total Liabilities 710,96M 590,59M 933,54M 920,23M 911,90M
Shareholders' Equity 1,82B 1,46B 1,20B 1,04B 1,11B
Total Debt 70,00M 75,54M 372,19M 379,44M 416,21M
Cash & Equivalents 1,12B 291,15M 457,47M 292,47M 337,54M
Current Assets 1,93B 1,42B 1,49B 1,13B 1,06B
Current Liabilities 543,44M 465,20M 520,22M 497,74M 471,29M